Abstract-Endothelial dysfunction because of nitric oxide inactivation has been suggested to play a role in the pathogenesis of preeclampsia. During pregnancy, L-arginine transport by CAT-1 (cationic amino acid transporter 1), the only transporter for eNOS (endothelial nitric oxide synthase) is inhibited. We hypothesize that maternal arginine deficiency contributes to the development of preeclampsia. Adenovirus-mediated overexpression of sFlt-1 (soluble fms-like tyrosine kinase 1) in virgin and pregnant mice resulted in glomerular endotheliosis, hypertension, and albuminuria. L-arginine prevented the increase in blood pressure and albuminuria in Flt-1 pregnant but not in Flt-1 virgin mice. Flt-1 augmented arginine transport in pregnant but not in virgin dames. Ex vivo inhibition of CAT-2 leaving exclusively CAT-1 activity, decreased arginine transport velocities in Flt-1 animals more prominently in pregnant dames. Phosphorylated CAT-1/CAT-1 increased in pregnant, sFlt-1-pregnant, and sFlt-1 virgin mice. CAT-2 increased in Flt-1-pregnant and Flt-1-virgin dames. L-arginine augmented arginine transport in pregnant and Flt-pregnant mice and prevented the increase in pCAT-1 and CAT-2 expression. Glomerular cGMP (cyclic guanosine monophosphate) generation as a measure of eNOS activity was decreased in all Flt-1 treated animals. L-arginine abolished the decrease in cGMP levels only in Flt-1-pregnant mice. In conclusion, glomerular endothelial NO generation is compromised in Flt-1-pregnant mice because of CAT-1 inhibition induced by a combined effect of pregnancy and preeclampsia which involves: phosphorylation of CAT-1 and induction of CAT-2. These processes contribute to the clinical syndrome of preeclampsia in mice and are prevented by L-arginine. (Hypertension.
P
reeclampsia is a serious complication of pregnancy that is characterized by increased blood pressure and proteinuria at the 20th week of gestation or later. It is the second cause of maternal death and the main cause of preterm birth. 1, 2 The cause of preeclampsia is still unclear. However, in preeclampsia, endothelial dysfunction is present, which causes an increase in vascular resistance, platelets aggregation, and activation of the coagulation system. 3 Endothelial dysfunction is characterized by an insufficient generation of vasodilator molecules, such as nitric oxide (NO), which is one of the main vasoactive endothelium-derived mediators. 4 During pregnancy, constitutive renal NO generation is augmented because of neuronal NO synthase (NOS) increased activity. 5 In contrast, in pregnancy accompanied by preeclampsia, there is an increase in the synthesis of ADMA (asymmetrical dimethyl arginine). 6 ADMA is an endogenous inhibitor of NOS, thus decreasing NO synthesis. [7] [8] [9] In addition, eclampsia induces accumulation of reactive oxygen species which inactivate NO and induce peroxynitrite accumulation. 10 Previous studies suggest that L-arginine, as the sole precursor for NO generation, governs NOS activity. Delivery of transported arginine to membrane-bound eNOS (endothelial nitric oxide synthase), selectively by CAT (cationic amino acid transporter)-1, rather than intracellular or extracellular arginine concentrations, is a predominant factor governing eNOS activity. 11 Indeed, we have shown in several different animal models that eNOS and CAT-1 activity act in concert. [12] [13] [14] [15] [16] [17] In glomeruli, CAT-1 was found exclusively in endothelial cells. 17 We have previously demonstrated that during normal pregnancy, maternal vasculature is subjected to diminished arginine uptake and this was attributed to CAT-1 phosphorylation by PKC-α (protein kinase C α). 13 Because the development of endothelial dysfunction is a hallmark of preeclampsia, a crucial issue raised by our observation is whether the decrease in arginine uptake during pregnancy provokes endothelial damage thus contributing to the development of preeclampsia.
Placental sFlt-1 (soluble fms-like tyrosine kinase 1), an antagonist of VEGF (vascular endothelial growth factor) and PlGF (placental growth factor), has been shown to play a pivotal role in the development of preeclampsia. 18 Eremina et al 19 demonstrated that dysregulation of VEGF plays a pathogenetic role in initiating glomerular injury phenotype mimicking preeclampsia. Therefore, using the above rodent model of pregnancy-induced hypertension and proteinuria, the current studies were designed to explore whether maternal glomerular arginine deficiency contributes to the development of preeclampsia.
Methods
The authors declare that all supporting data are available within the article and its in the online-only Data Supplement. All animal procedures described in this study were conducted in accordance with the guide for the care and use of laboratory animals published by the Israeli ministry of health and approved by the institutional animal care and use committee. All standard reagents were obtained from Sigma Chemical Co unless indicated otherwise. H3 L-Arginine was supplied by Perkin Elmar, Life and Analytical Sciences (Boston, Mass). Studies were performed using CD-1 (Hsd:ICR) female mice (ENVIGO) at 8 to 10 weeks of age. The mice were hosted in temperature and humidity-controlled cages with constant light-dark cycles of 12 hours:12 hours. They were provided with food and water ad libitum. Subsequently, animals were segregated into the following experimental groups (n=12-15 mice /group):
Group 1: Control: Sham-treated mice were injected through the tail vein at day 7 to 8 of the experiment with 3×10 9 PFU/100 µL of adenovirus encoding murine Fc protein (Ad Fc). Ad Fc was used as a control to rule out nonspecific effects of adenovirus.
Group 2: Pregnancy: Mice destined to become pregnant were housed with a male breeder of the same strain for 48 hours. Day one of pregnancy was documented by the presence of spermatozoa in the vaginal lavage.
Group 3: Preeclampsia in pregnancy (Pregnancy+FLT): Pregnant dames were injected through the tail vein at day 7 to 8 of gestation, with 3×10 9 PFU/100 µL of adenovirus to overexpress sFlt-1 (Ad sFlt-1, Vector Biolabs, Philadelphia, PA).
Group 4: Preeclampsia in virgin mice (control+FLT): Flt-1 was administered to virgin animals as in group 3.
Experimental procedures were performed 10 days following the administration of the vector. Additional mice from each group were treated with L-arginine 3% in the drinking water starting 5 days before the administration of the vector until euthanization (n=6 per each group). Hydralazine 25 mg/kg BW in the drinking water was administered to dames from group 3 (n=6). Animals were euthanized using CO 2 .
An expanded methods section is available in the online-only Data Supplement.
Statistical Analysis
Data are presented as mean±SE. One way ANOVA was conducted for comparison between groups. Post hoc analysis using the LSD algorithm was performed to allocate the source of significance.
Results
Transfection with sFlt-1 resulted in a significant increase in serum sFLT-1 levels. Animals subjected to the vector did not exhibit a significant change in body weight, water intake, serum creatinine, or albumin levels (Table S1 in the online-only Data Supplement). The number of pups and placentas was not different among all experimental groups. Representative light microscopy of renal glomeruli illustrates the endotheliosis and mesangial expansion induced by sFlt-1. Kidneys from arginine-treated Flt-1-pregnant dames had more open capillaries and distinct mesangium compared with the untreated corresponding experimental group and hydralazine Flt-1-pregnant animals (Figure 1 ), while no significant changes were observed in the arginine-treated Flt-1 virgin mice ( Figures S1 and S2) .
Pregnant mice exhibited a significantly lower blood pressure measurements compared with controls. After sFlt-1 transfection, in both pregnant and virgin mice, blood pressure was significantly higher than in corresponding vehicle-treated animals. The administration of L-arginine in the drinking water notably alleviated the increase in blood pressure in sFlt-1 pregnant mice but not in virgin sFlt-1-treated animals ( Figure 2A ).
We next tested the effects of arginine on urinary albumin excretion in all experimental groups. sFlt-1 increased urinary albumin excretion in both pregnant and virgin mice. Likewise, in sFlt-1 transfected pregnant mice, L-arginine significantly attenuated the increase in urinary albumin excretion, while it had no effect in sFlt-1 transfected virgin dames ( Figure 2B ). To delineate between blood pressure and local glomerular effects of L-arginine, hydralazine was administered to sFlt-1 transfected pregnant mice to decrease blood pressure values to the corresponding arginine-treated group (112±10 versus 110±8 mm Hg). The decrease in urinary albumin excretion by L-arginine was significantly higher than with hydralazine ( Figure 2C ).
To explore the effect of Flt-1 and gestation on CAT system, glomerular arginine uptake was determined ( Figure 3 ). In concordance with our previous findings in rats, glomerular arginine transport remarkably decreased during pregnancy. Transfection with sFlt-1 significantly augmented glomerular arginine transport in pregnant dames, while arginine transport velocities in sFlt-1-treated virgin mice were not different from control animals. L-arginine given in the drinking water significantly increased arginine transport only in pregnant but not in the virgin experimental groups. The effect of arginine in the sFlt-1 pregnant animals was exceptionally higher than in pregnant animals (6.9 versus 3.8 nmol arginine/mg protein, P<0.01). Arginine transport following ex vivo administration of L-NIL (N6-(1-iminoethyl)-lysine hydrochloride; a selective iNOS [inducible NOS] inhibitor) in control and untreated pregnant mice remained unchanged. However, it was significantly decreased in both sFlt-1 treated groups. Of note, the effect was more profound in sFlt-1 pregnant mice than in sFlt-1 virgin dames (1.2 versus 3.1 nmol arginine/mg protein, P<0.01).
To determine whether the changes in arginine uptake are associated with parallel directional changes in CAT-1 and CAT-2, the glomerular corresponding proteins were evaluated ( Figure 4 ). We have found that CAT-1 protein content significantly decreased in pregnant, sFlt-1 transfected pregnant and virgin dames, and arginine-treated pregnant mice. In contrast, it was profoundly increased in sFlt-1 transfected pregnant mice treated with arginine ( Figure 4A and 4B) . Subsequently, we have also found that phosphorylated CAT-1 increased in pregnant and sFLT-1 transfected pregnant and virgin mice. The administration of L-arginine prevented the increase in phosphorylated CAT-1 in sFLT-1 transfected virgin mice and almost completely abolished its abundance in pregnant and sFLT-1 transfected pregnant dames ( Figure 4C and 4D) .
Our results show that CAT-2 protein decreased during pregnancy and increased in sFlt-1 transfected pregnant and virgin dames. Treatment with L-arginine prevented the decrease in CAT-2 during pregnancy as well as its increased abundance following sFlt-1 transfection ( Figure 4E and 4F) .
Finally, we measured glomerular cGMP generation, following stimulation with Carbamyl Choline, a selective eNOS agonist, with and without the coadministration of L-NAME (L-N-nitroarginine methyl ester hydrochloride; NOS inhibitor). We used the difference between these values as an index of eNOS activity ( Figure 5A ). As shown, eNOS activity was unchanged in pregnant dames but was significantly decreased in all sFlt-1 treated animals (both pregnant and virgins). L-arginine administration completely prevented the decrease in cGMP levels exhibited in sFlt-1 overexpressing pregnant animals, while vehicle-treated animals were unaffected. Then, glomerular cGMP was measured following the systemic administration of 7-NI (7 nitroindasol; neuronal NOS antagonist).
No differences were found between animals pretreated with 7-NI and vehicle in all experimental groups, suggesting that glomerular constitutive NO generation in our experimental model derives predominantly from eNOS ( Figure 5B) .
Additionally, the diminished glomerular eNOS abundance of both sFlt-1 treated virgin and pregnant mice was also prevented by L-arginine supplementation ( Figure 5C and 5D ).
Discussion
The present study, in a mouse model of preeclampsia, demonstrates that several different mechanisms merge to profoundly inhibit glomerular arginine transport attributed to impaired CAT-1 activity. However, when all these processes are ameliorated by L-arginine treatment, the clinical features of preeclampsia are significantly attenuated. This beneficial effect of L-arginine is not related to changes in blood pressure since lowering blood pressure in pregnant preeclamptic dames by hydralazine failed to decrease proteinuria to a similar level, supporting a local, glomerular mechanism.
Similar to our previous observation in pregnant rats, 13 pregnant mice also exhibit a significant drop in arginine transport velocities associated with a decrease in CAT-1 protein content and increase in phosphorylated CAT-1 (the transporter inactive form). Although CAT-2 expression was also decreased, we tend to attribute the pregnancy-induced decrease in arginine uptake solely to altered CAT-1 activity. Glomerular CAT-2 is an inducible transporter, and its role in constitutive arginine uptake is questionable. 20, 21 Moreover, no significant changes in arginine uptake were observed when CAT-2 inhibitor was applied to glomeruli harvested from control mice, implying that the contribution of CAT-2 to the decrease in arginine uptake during pregnancy is negligible. Since endothelial dysfunction associated with eNOS inactivation is one of the hallmarks of preeclampsia, we anticipated to observe a further reduction in arginine transport following sFlt-1 transfection in pregnant mice. Surprisingly, arginine uptake in preeclamptic dames was similar to controls and higher than in pregnancy. As arginine traffic measurements in our experimental model is the sum of all arginine transporters which are active within the glomerular milieu, we aimed to isolate the contribution of CAT-1 by applying, ex vivo, a CAT-2 inhibitor. For this purpose, we used L-NIL (a selective iNOS inhibitor), based on a well established association between iNOS and CAT-2 activity, in both renal and nonrenal tissues. [20] [21] [22] Subjecting glomeruli to CAT-2 inhibition resulted in a profound decrease in arginine transport in pregnant preeclamptic mice compared with all other experimental groups. Most importantly, this decline was highly significant when compared with pregnant and sFlt-1 treated virgin animals. Taken together, our data suggest that, in contrast to pregnancy, in preeclampsia glomerular CAT-2 is upregulated and significantly contributes to glomerular arginine influx. Indeed, these findings are supported by the increased CAT-2 protein expression observed in sFlt-1 transfected dames. In contrast, CAT-1 activity is severely compromised. CAT-1 inhibition in preeclampsia is multifactorial. The increase in pCAT-1/CAT-1 ratio observed in pregnancy is further aggravated in the preeclamptic mice. We have recently proposed 2 different mechanisms to explain the decrease in arginine transport during pregnancy: we have demonstrated, in endothelial cell cultures, that the 2 main female sex hormones, estrogen and progesterone, exert an opposite effect on NO generation through modulation of CAT-1. Estrogen was found to augment whereas progesterone attenuates arginine transport velocities and NOS. Therefore, we have suggested that during pregnancy, the negative effect of progesterone overcomes that of estrogen, leading to diminished endothelial arginine transport. 23 In another set of experiments, VEGF have been shown to increase arginine transport in endothelial cells and this effect was exclusively mediated by KDR (kinase insert domain receptor; VEGFR2) but not Flt-1. 24 Taken together, one can hypothesize, that the overwhelming increase in sFlt-1 levels during preeclampsia prevents VEGF from binding KDR, thus leading to further inhibition of CAT-1. The current experiments provide an additional mechanism which links preeclampsia to CAT-1 inactivation that involves CAT-2 upregulation. sFlt-1 transfection resulted in a significant upregulation of glomerular CAT-2. The aforementioned results are with an agreement with McCord et al 25 who demonstrated that CAT-2 is activated in peripheral blood mononuclear cells from preeclamptic females. Modulation of one transporter has been found to dictate changes in the expression of another transporter. In vivo administration of lipopolysaccharide augmented glomerular arginine transport through upregulation of CAT-2 while CAT-1 was downregulated. 20 We had similar findings when we studied the effect of BH4 (tetrahydrobiopterin) on CAT-1 and CAT-2 mRNA expression in rat cardiac myocytes We hypothesized that upregulation of an individual CAT may lead to decreased expression of the other transporters via a direct effect. 26 ADMA levels have been shown to be elevated in preeclampsia. 6 CAT proteins transport ADMA both into and out of cells, resulting in an exchange of CATs between both sides of the membrane. Therefore, these L-arginine analogs not only compete with L-arginine influx but are also capable of driving out intracellular L-arginine. 27 Increased circulatory ADMA levels have been documented in several animal models of endothelial dysfunction as well as in uremic patients and contribute to the development of endothelial dysfunction. 28, 29 Taken together, in agreement with our previous studies, we think that ADMA excess during preeclampsia has a significant additional role in CAT-1 inhibition.
To further clarify these complex interactions between pregnancy, preeclampsia, and the CAT system, we chose to perform studies comparing between the effects of sFlt-1 transfection in pregnant and in virgin mice. CAT-1 activity was significantly lower in the sFlt transfected pregnant dames compared with virgin preeclamptic animals. These findings are reasonable and are supported by the presence of elevated pCAT-1 and CAT-2 upregulation which were significantly more apparent in the pregnant preeclamptic versus virgin preeclampic animals. Moreover, treatment with L-arginine completely prevented the decrease in glomerular arginine transport and effectively attenuated the increase in blood pressure and albuminuria in the pregnant preeclamptic dames while it proved to be ineffective in the virgin preeclamptic animals. In the aggregate, our data suggest that, in pregnancy complicated by preeclampsia there is a profound inhibition of glomerular arginine uptake by CAT-1, which proves to play a crucial role in this model of preeclampsia. Interestingly, arginine supplementation successfully abolished all pathways which may lead to CAT-1 inactivation. We have previously shown in several different experimental models characterized by endothelial dysfunction and CAT-1/eNOS inactivation that arginine administration prevents CAT-1 phosphorylation by PKC-α. 12, 13 In addition, the administration of arginine is also expected to ameliorate the deleterious effects of high serum ADMA concentration on the CAT-1/eNOS system. In contrast, the inhibitory effect of arginine on CAT-2 is obscure. Meng et al 30 have shown that arginine uptake by CAT-1 prevents NF-κB (nuclear factor κB) upregulation and CAT-2 activity in Caco-2 cell culture providing a possible mechanism to explain the aforementioned observation. Taken together: in preeclampsia, 3 different mechanisms namely: CAT-1 phosphorylation, CAT-2 activation, and ADMA accumulation synergistically inhibit glomerular CAT-1 activity (Figure 6 ).
Beneficial effects of L-arginine treatment have been demonstrated in numerous animal models of endothelial dysfunction, yet, clinical trials have failed to prove its efficacy in patients. 31, 32 In contrast, an overall positive effect for arginine treatment characterized clinical trials in women with preeclampsia. Dorniak-Wall et al 33 reviewed 7 randomized trials, with a combined sample size of 884 women: In women at risk of preeclampsia, L-arginine administration was associated with a reduction in preeclampsia when compared with placebo and a reduction in risk of preterm birth in women with established hypertensive disease. They have concluded that further well-designed and adequately powered trials are warranted, both in women at risk of preeclampsia and in women with established disease.
Intracellular arginine availability impacts vascular reactivity primarily through modulation of endothelial NO generation. Indeed, the present study, in agreement with previous publications, 4, [6] [7] [8] [9] [10] demonstrated a decrease in eNOS activity during preeclampsia. In contrast, eNOS inactivation in pregnant animals failed to produce hypertension. 34, 35 These apparent discrepancies can be resolved by the fact that in preeclampsia, changes in the activity of other vasoactive substances (eg, endothelin-1) as well as immunologic processes act in concert with altered NO to damage the endothelium of pregnant preeclamptic females. 36 In conclusion, glomerular endothelial NO generation is significantly compromised during sFlt-1 transfection in pregnant mice because of combined pregnancy and preeclampsia induced CAT-1 inhibition which involves multiple mechanisms. The combined effect of these processes contributes to the clinical syndrome in a mouse model of preeclampsia and can be completely prevented by exogenous L-arginine treatment.
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